Skip to main content Accessibility help
×
Home
  • Print publication year: 2006
  • Online publication date: September 2009

4 - Surgical Management of Patients with Epithelial Ovarian Cancer

Related content

Powered by UNSILO
REFERENCES
Jemal, A., Tiwari, R. C., Murray, T., et al. American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin (2004), 54:8–29.
Benedet, J. L., Hacker, N. F. and Ngan, H. Y. S., eds. Staging Classifications and Clinical Practice Guidelines of Gynaecological Cancers, 2nd Edition. FIGO Committee on Gynecologic Oncology and IGCS Guidelines Committee, 2003. Reprinted from Int J Gynecol Obstet (2000), 70:207–312.
Young, R. C., Decker, D. G., Wharton, J. T., et al. Staging laparotomy in early ovarian cancer. JAMA (1983), 250:3072–6.
Soper, J. T., Johnson, P., Johnson, V., et al. Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma. Obstet Gynecol (1992), 80:949–53.
Eisenkop, S. M. and Spirtos, N. M.. The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecol Oncol (2001), 82:143–9.
Morice, P., Joulie, F., Camatte, S., et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. Am Coll Surg (2003), 197:198–205.
Trimbos, J. B., Vergote, I., Bolis, G., et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst (2003), 95:113–25.
Griffiths, C. T.. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr (1975), 42:101–4.
Prefontaine, M., Gelfand, A. T., Donovan, J. T. and Powell, J. L.. Reproducibility of tumor measurements in ovarian cancer: a study of interobserver variability. Gynecol Oncol (1994), 55:87–90.
Hoskins, W. J., McGuire, W. P., Brady, M. F., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol (1994), 170:974–9.
Hunter, R. W., Alexander, N. D. and Soutter, W. P.. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?Am J Obstet Gynecol (1992), 166:504–11.
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol (2002), 20:1248–59.
Eisenkop, S. M., Friedman, R. L. and Wang, H. J.. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol (1998), 69:103–8.
Allen, D. G. and Coulter, J.. Survival of patients with epithelial ovarian cancer and the effect of lymphadenectomy in those with stage 3 disease. Aust NZ J Obstet Gynaecol (1999), 39:420–4.
Kikkawa, F., Ishikawa, H., Tamakoshi, K., et al. Prognostic evaluation of lymphadenectomy for epithelial ovarian cancer. J Surg Oncol (1995), 60:227–31.
Yokoyama, Y., Sakamoto, T., Sato, S., et al. Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer. Eur J Gynaecol Oncol (1999), 20:361–6.
Benedetti-Panici, B., Maggioni, A., Hacker, N., et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst (2005), 97:560–6.
Kehoe, S., Powell, J., Wilson, S., et al. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer (1994), 70:1014–17.
Nguyen, H. N., Averette, H. E., Hoskins, W., et al. National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer (1993), 72:3663–70.
Giede, K. C., Kieser, K., Dodge, J., et al. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol (2005), 99:447–61.
Junor, E. J., Hole, D. J., McNulty, L., et al. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1,866 patients. Br J Obstet Gynaecol (1999), 106:1130–6.
Junor, E. J., Hole, D. J. and Gillis, C. R.. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer (1994), 70:363–70.
Covens, A. L.. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol (2000), 78:269–74.
Hacker, N. F., Berek, J. S., Lagasse, L. D., et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol (1983), 61:413–20.
Hoskins, W. J., Bundy, B. N., Thigpen, J. T., et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol (1992), 47:159–66.
Crawford, S. C., Vasey, P. A., Paul, J., et al. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol (2005), 23:8802–11.
Vasey, P. A., Jayson, G. C., Gordon, A., et al. Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst (2004), 96:1682–91.
Brockbank, E. C., Ind, T. E., Barton, D. P., et al. Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer (2004), 14:42–50.
Jacob, J. H., Gershenson, D. M., Morris, M., et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol (1991), 42:146–50.
Onnis, A., Marchetti, M., Padovan, P., et al. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynaecol Oncol (1996), 17:393–6.
Schwartz, P. E., Rutherford, T. J., Chambers, J. T., et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol (1999), 72:93–9.
Ushijima, K., Ota, S., Komai, K., et al. Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. Int Surg (2002), 87:185–90.
Vrscaj, M. U. and Rakar, S.. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study. Eur J Gynaecol Oncol (2002), 23:405–10.
Kuhn, W., Rutke, S., Spathe, K., et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer (2001), 92:2585–91.
Vergote, I. B., Wever, I., Decloedt, J., et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol (2000), 27 (Suppl 7):31–6.
Vergote, I., Wever, I., Tjalma, W., et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol (1998), 71:431–6.
Volz, J., Koster, S., Spacek, Z., et al. The influence of pneumoperitoneum used in laparoscopic surgery on an intraabdominal tumor growth. Cancer (1999), 86:770–4.
Abu-Rustum, N. R., Sonoda, Y., Chi, D. S., et al. The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer. Gynecol Oncol (2003), 90:431–4.
Abu-Rustum, N. R., Rhee, E. H., Chi, D. S., et al. Subcutaneous tumor implantation after laparoscopic procedures in women with malignant disease. Obstet Gynecol (2004), 103:480–7.
Nagarsheth, N. P., Rahaman, J., Cohen, C. J., et al. The incidence of port-site metastases in gynecologic cancers. JSLS (2004), 8:133–9.
Cavina, E., Goletti, O., Molea, N., et al. Trocar site tumor recurrences. May pneumoperitoneum be responsible?Surg Endosc (1998), 12:1294–6.
Dowdy, S. C., Mullany, S. A., Brandt, K. R., et al. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer (2004), 101:346–52.
Everett, E. N., Heuser, C. C., Pastore, L. M., et al. Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer. Am J Obstet Gynecol (2005), 193:568–74.
Qayyum, A., Coakley, F. V., Westphalen, A. C., et al. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol (2005), 96:301–6.
Bristow, R. E., Duska, L. R., Lambrou, N. C., et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer (2000), 89:1532–40.
Nelson, B. E., Rosenfield, A. T. and Schwartz, P. E.. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol (1993), 11:166–72.
Forstner, R., Hricak, H., Occhipinti, K. A., et al. Ovarian cancer: staging with CT and MR imaging. Radiology (1995), 197:619–26.
Burg, M. E., Lent, M., Buyse, M., et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med (1995), 332:629–34.
Rose, P. G., Nerenstone, S., Brady, M. F., et al. Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med (2004), 351:2489–97.
Harter, P. and Bois, A. du. The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Curr Opin Oncol (2005), 17:505–14.
Eisenkop, S. M., Friedman, R. L. and Spirtos, N. M.. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer (2000), 88:144–53.
Dvoretsky, P. M., Richards, K. A., Angel, C., et al. Survival time, causes of death, and tumor/treatment-related morbidity in 100 women with ovarian cancer. Hum Pathol (1988), 19:1273–9.
Tunca, J. C., Buchler, D. A., Mack, E. A., et al. The management of ovarian-cancer-caused bowel obstruction. Gynecol Oncol (1981), 12:186–92.
Pothuri, B., Vaidya, A., Aghajanian, C., et al. Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. Gynecol Oncol (2003), 89:306–13.
Feuer, D. J., Broadley, K. E., Shepherd, J. H., et al. Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. The Systematic Review Steering Committee. Gynecol Oncol (1999), 75:313–22.
Krebs, H. B. and Goplerud, D. R.. Surgical management of bowel obstruction in advanced ovarian carcinoma. Obstet Gynecol (1983), 61:327–30.
Vera-Garcia, C.. A patient's perspective on ovarian cancer as a chronic disease – devaluing a survivor's challenge. Gynecol Oncol (2005), 96:19–20.